These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 26699406)

  • 1. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
    Navari RM
    Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
    Navari RM
    Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
    Rapoport B; van Eeden R; Smit T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
    Einhorn LH; Rapoport B; Navari RM; Herrstedt J; Brames MJ
    Support Care Cancer; 2017 Jan; 25(1):303-308. PubMed ID: 27815710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
    Morrow GR; Navari RM; Rugo HS
    Clin Adv Hematol Oncol; 2014 Mar; 12(3 Suppl 9):1-14; quiz 15. PubMed ID: 24874107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
    Rapoport B; Smit T
    Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis.
    Patel P; Paw Cho Sing E; Dupuis LL
    Expert Opin Drug Saf; 2019 Feb; 18(2):97-110. PubMed ID: 30640557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
    Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults.
    Karthaus M; Schiel X; Ruhlmann CH; Celio L
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):661-680. PubMed ID: 31194593
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.
    Orhan A; Nguyen C; Chan A; Herrstedt J
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):473-489. PubMed ID: 38878283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Rugo HS; Aapro MS
    Clin Adv Hematol Oncol; 2015 Mar; 13(3 Suppl 3):3-13, 1; quiz 2 p following 14. PubMed ID: 25856052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.